Eli Lilly to Acquire Centessa Pharmaceuticals in a Deal Valued at ~$7.8B

Shots: Eli Lilly has entered into a definitive agreement to acquire Centessa Pharmaceuticals incl. its asset cleminorexton & ORX142, expanding Lilly's neuroscience portfolio & capabilities into sleep medicine As per the deal, Lilly will acquire all issued & to-be-issued share capital of Centessa (incl. ADSs) for $38/share in cash (~$6.3B upfront), plus a non-transferable CVR of…

ByRidhi Rastogi16 hours ago

NEWS

CVC Capital Partners Proposes ~€10.9B Acquisition of Recordati

Shots: Recordati has received a non-binding indication of interest from CVC Capital Partners for a voluntary tender offer to acquire all outstanding shares & delist the company, subject to due diligence, financing, & partner identification Recordati expanded into rare diseases with its 2021 acquisition of EUSA Pharma for ~$845M, strengthening its rare cancer portfolio The…

ByRidhi Rastogi18 hours ago

NEWS

Otsuka to Acquire Transcend Therapeutics for ~$1.225B

Shots: Otsuka, via its subsidiary Otsuka America, has entered into an agreement to fully acquire Transcend, with an aim to expand its portfolio in psychiatric & neurological indications As per the deal, Otsuka will acquire Transcend for $700M upfront, & ~$525M in sales milestones, representing the total deal value of ~$1.225B; closing is expected in…

ByRidhi Rastogi2 days ago

NEWS

Novartis to Acquire Excellergy for ~$2B

Shots: Novartis has entered into an agreement to acquire Excellergy, incl. its asset Exl-111, strengthening Novartis immunology strategy in food allergy & other IgE-driven diseases As per the deal, Novartis will acquire Excellergy for ~$2B, incl. upfront & milestone payments, with closing expected in H2’26 EXL-111 is engineered to dissociate receptor-bound IgE, enabling faster &…

ByRidhi Rastogi5 days ago

NEWS

Merck to Acquire Terns Pharmaceuticals for ~$6.7B

Shots: Merck has entered into a definitive agreement to acquire Terns, incl. its asset TERN-701 asset, expanding its oncology pipeline As per the deal, Merck will acquire Terns for $53/share in cash, representing a total equity value of ~$6.7B (~$5.7B net of acquired cash); closing is expected in Q2’26 TERN-701 is being evaluated in the…

ByRidhi RastogiMarch 25, 2026

NEWS

Gilead to Acquire Ouro Medicine for ~$2.1B

Shots: Gilead to acquire Ouro for a total of $1,675M in upfront cash & up to $500M in contingent milestone payments. Acquisition will add Ouro’s P-I/II asset OM336 (gamgertamig) to Gilead’s inflammation portfolio, with registrational studies to begin in 2027 Also, Gilead is in advanced discussions with Galapagos for a potential R&D collaboration on the…

ByRidhi RastogiMarch 24, 2026

NEWS

Embecta to Acquire Owen Mumford for ~£150M

Shots: Embecta has entered into a definitive agreement to acquire Owen Mumford, expanding drug-delivery capabilities & strengthening global presence in the chronic care market As per the deal, Embecta will acquire Owen Mumford for ~£150M (~$199.9M), incl. £100M (~$133.2M) upfront & up to £50M (~$66.6M) in sales-based milestones tied to Aidaptus, with closing expected in…

ByRidhi RastogiMarch 20, 2026

NEWS

Medtronic to Acquire Scientia Vascular for $550M

Shots: Medtronic has entered into a definitive agreement to acquire Scientia Vascular, expanding its neurovascular device portfolio As per the deal, Medtronic will acquire Scientia Vascular for $550M, with potential undisclosed earn-out & milestone payments post-acquisition Acquisition will integrate Scientia’s access platform with Medtronic’s neurovascular therapies to support the full procedural workflow for hemorrhagic &…

ByRidhi RastogiMarch 11, 2026

NEWS

Agilent Technologies to Acquire Biocare Medical for $950M

Shots: Agilent Technologies has entered into a definitive agreement to acquire Biocare Medical from investor groups led by Excellere Partners & GHO Capital Partners As per the deal, Agilent will acquire Biocare in an all-cash transaction valued at $950M, with closing anticipated by Q4’26, after which Biocare will become a part of the Agilent Life…

ByRidhi RastogiMarch 10, 2026

NEWS

Servier to Acquire Day One Biopharmaceuticals for ~$2.5B

Shots: Servier has entered into a definitive agreement to acquire Day One Biopharmaceuticals As per the deal, Servier will acquire Day One for $21.5/share in cash, representing the total equity value of ~$2.5B, with remaining shares acquired later via a second-step merger; closing expected in Q2’26 Acquisition will strengthen Servier’s leadership in pediatric low-grade glioma…

ByRidhi RastogiMarch 9, 2026

Eli Lilly to Acquire Centessa Pharmaceuticals in a Deal Valued at ~$7.8B

CVC Capital Partners Proposes ~€10.9B Acquisition of Recordati

Otsuka to Acquire Transcend Therapeutics for ~$1.225B

Novartis to Acquire Excellergy for ~$2B

Merck to Acquire Terns Pharmaceuticals for ~$6.7B

Gilead to Acquire Ouro Medicine for ~$2.1B

Embecta to Acquire Owen Mumford for ~£150M

Medtronic to Acquire Scientia Vascular for $550M

Agilent Technologies to Acquire Biocare Medical for $950M

Servier to Acquire Day One Biopharmaceuticals for ~$2.5B

Contact US

FOLLOW US